Cargando…
Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging
PURPOSE: Recently we showed that a number of carboxylated near-infrared fluorescent (NIRF) cyanine dyes possess strong necrosis avid properties in vitro as well as in different mouse models of spontaneous and therapy-induced tumor necrosis, indicating their potential use for cancer diagnostic- and p...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093207/ https://www.ncbi.nlm.nih.gov/pubmed/27277828 http://dx.doi.org/10.1007/s11307-016-0972-7 |
_version_ | 1782464870499745792 |
---|---|
author | Stammes, Marieke A. Knol-Blankevoort, Vicky T. Cruz, Luis J. Feitsma, Hans R. I. J. Mezzanotte, Laura Cordfunke, Robert A. Sinisi, Riccardo Dubikovskaya, Elena A. Maeda, Azusa DaCosta, Ralph S. Bierau, Katja Chan, Alan Kaijzel, Eric L. Snoeks, Thomas J. A. van Beek, Ermond R. Löwik, Clemens W. G. M. |
author_facet | Stammes, Marieke A. Knol-Blankevoort, Vicky T. Cruz, Luis J. Feitsma, Hans R. I. J. Mezzanotte, Laura Cordfunke, Robert A. Sinisi, Riccardo Dubikovskaya, Elena A. Maeda, Azusa DaCosta, Ralph S. Bierau, Katja Chan, Alan Kaijzel, Eric L. Snoeks, Thomas J. A. van Beek, Ermond R. Löwik, Clemens W. G. M. |
author_sort | Stammes, Marieke A. |
collection | PubMed |
description | PURPOSE: Recently we showed that a number of carboxylated near-infrared fluorescent (NIRF) cyanine dyes possess strong necrosis avid properties in vitro as well as in different mouse models of spontaneous and therapy-induced tumor necrosis, indicating their potential use for cancer diagnostic- and prognostic purposes. In the previous study, the detection of the cyanines was achieved by whole body optical imaging, a technique that, due to the limited penetration of near-infrared light, is not suitable for investigations deeper than 1 cm within the human body. Therefore, in order to facilitate clinical translation, the purpose of the present study was to generate a necrosis avid cyanine-based NIRF probe that could also be used for single photon emission computed tomography (SPECT). For this, the necrosis avid NIRF cyanine HQ4 was radiolabeled with (111)indium, via the chelate diethylene triamine pentaacetic acid (DTPA). PROCEDURES: The necrosis avid properties of the radiotracer [(111)In]DTPA-HQ4 were examined in vitro and in vivo in different breast tumor models in mice using SPECT and optical imaging. Moreover, biodistribution studies were performed to examine the pharmacokinetics of the probe in vivo. RESULTS: Using optical imaging and radioactivity measurements, in vitro, we showed selective accumulation of [(111)In]DTPA-HQ4 in dead cells. Using SPECT and in biodistribution studies, the necrosis avidity of the radiotracer was confirmed in a 4T1 mouse breast cancer model of spontaneous tumor necrosis and in a MCF-7 human breast cancer model of chemotherapy-induced tumor necrosis. CONCLUSIONS: The radiotracer [(111)In]DTPA-HQ4 possessed strong and selective necrosis avidity in vitro and in various mouse models of tumor necrosis in vivo, indicating its potential to be clinically applied for diagnostic purposes and to monitor anti-cancer treatment efficacy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11307-016-0972-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5093207 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-50932072016-11-17 Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging Stammes, Marieke A. Knol-Blankevoort, Vicky T. Cruz, Luis J. Feitsma, Hans R. I. J. Mezzanotte, Laura Cordfunke, Robert A. Sinisi, Riccardo Dubikovskaya, Elena A. Maeda, Azusa DaCosta, Ralph S. Bierau, Katja Chan, Alan Kaijzel, Eric L. Snoeks, Thomas J. A. van Beek, Ermond R. Löwik, Clemens W. G. M. Mol Imaging Biol Research Article PURPOSE: Recently we showed that a number of carboxylated near-infrared fluorescent (NIRF) cyanine dyes possess strong necrosis avid properties in vitro as well as in different mouse models of spontaneous and therapy-induced tumor necrosis, indicating their potential use for cancer diagnostic- and prognostic purposes. In the previous study, the detection of the cyanines was achieved by whole body optical imaging, a technique that, due to the limited penetration of near-infrared light, is not suitable for investigations deeper than 1 cm within the human body. Therefore, in order to facilitate clinical translation, the purpose of the present study was to generate a necrosis avid cyanine-based NIRF probe that could also be used for single photon emission computed tomography (SPECT). For this, the necrosis avid NIRF cyanine HQ4 was radiolabeled with (111)indium, via the chelate diethylene triamine pentaacetic acid (DTPA). PROCEDURES: The necrosis avid properties of the radiotracer [(111)In]DTPA-HQ4 were examined in vitro and in vivo in different breast tumor models in mice using SPECT and optical imaging. Moreover, biodistribution studies were performed to examine the pharmacokinetics of the probe in vivo. RESULTS: Using optical imaging and radioactivity measurements, in vitro, we showed selective accumulation of [(111)In]DTPA-HQ4 in dead cells. Using SPECT and in biodistribution studies, the necrosis avidity of the radiotracer was confirmed in a 4T1 mouse breast cancer model of spontaneous tumor necrosis and in a MCF-7 human breast cancer model of chemotherapy-induced tumor necrosis. CONCLUSIONS: The radiotracer [(111)In]DTPA-HQ4 possessed strong and selective necrosis avidity in vitro and in various mouse models of tumor necrosis in vivo, indicating its potential to be clinically applied for diagnostic purposes and to monitor anti-cancer treatment efficacy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11307-016-0972-7) contains supplementary material, which is available to authorized users. Springer US 2016-06-08 2016 /pmc/articles/PMC5093207/ /pubmed/27277828 http://dx.doi.org/10.1007/s11307-016-0972-7 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Research Article Stammes, Marieke A. Knol-Blankevoort, Vicky T. Cruz, Luis J. Feitsma, Hans R. I. J. Mezzanotte, Laura Cordfunke, Robert A. Sinisi, Riccardo Dubikovskaya, Elena A. Maeda, Azusa DaCosta, Ralph S. Bierau, Katja Chan, Alan Kaijzel, Eric L. Snoeks, Thomas J. A. van Beek, Ermond R. Löwik, Clemens W. G. M. Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging |
title | Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging |
title_full | Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging |
title_fullStr | Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging |
title_full_unstemmed | Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging |
title_short | Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging |
title_sort | pre-clinical evaluation of a cyanine-based spect probe for multimodal tumor necrosis imaging |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093207/ https://www.ncbi.nlm.nih.gov/pubmed/27277828 http://dx.doi.org/10.1007/s11307-016-0972-7 |
work_keys_str_mv | AT stammesmariekea preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging AT knolblankevoortvickyt preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging AT cruzluisj preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging AT feitsmahansrij preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging AT mezzanottelaura preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging AT cordfunkeroberta preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging AT sinisiriccardo preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging AT dubikovskayaelenaa preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging AT maedaazusa preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging AT dacostaralphs preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging AT bieraukatja preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging AT chanalan preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging AT kaijzelericl preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging AT snoeksthomasja preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging AT vanbeekermondr preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging AT lowikclemenswgm preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging |